HVEM – BTLA – LIGHT – CD160 Network

HVEM (CD270; TNFRSF14) is a molecular switch that acts both as an immune system stimulator and as an inhibitor. It is expressed in T cells, B cells, natural killer cells, dendritic cells and endothelial cells. LIGHT is an immune stimulator that contributes to dendritic cell maturation and T cell expansion. The immune suppressor BTLA functions in opposition to LIGHT in suppression of naïve T cell expansion and induction of Treg cells. CD160 acts as an immune suppressor through its interactions with HVEM. The checkpoint receptors/ligands system HVEM, LIGHT, CD160 and BTLA (CD272) is part of a complex network of overlapping receptor interactions that function in both immune stimulation and suppression and which is a potential therapeutic target for treatment of autoimmune diseases and allergies and controlling antitumor responses.

LIT: Identification of CD112R as a novel checkpoint for human T cells: Y. Zhu, et al.; J. Exp. Med. 213, 167 (2016) • Cosignaling molecules around LIGHT-HVEMBTLA: from immune activation to therapeutic targeting: C. Pasero, et al.; Curr. Mol. Med. 9, 911 (2009) • HVEM/LIGHT/BTLA/CD160 cosignaling pathways as targets for immune regulation: M.L. del Rio, et al.; J. Leukoc. Biol. 87, 223 (2010)

Biologically Active HVEM, BTLA, CD160 and LIGHT Proteins  

VALIDATED Antibodies for BTLA and HVEM Research

Select Your Pathway of Interest  & Discover High Quality Reagents